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AbstrACt
Objectives Patients with diabetes mellitus are at a risk 
for hypoglycaemia. Besides the burden of hypoglycaemia 
for patients, hypoglycaemia poses an economic burden 
to society. The aim of this study was to calculate the per 
patient societal costs of hypoglycaemia among patients 
with type1 diabetes (T1DM) and type 2 diabetes (T2DM) on 
insulin therapy in the Netherlands.
Methods To calculate the costs of hypoglycaemia, data 
from the Global Hypoglycaemia Assessment Tool (HAT) 
study were used. Dutch patients were selected from 
the HAT study database and data regarding healthcare 
resource use, informal care use and productivity losses 
were combined with Dutch unit costs to calculate the 
per patient 4-week costs of patients experiencing 
hypoglycaemia. Besides these 4-week costs, costs per 
hypoglycaemic event were calculated by dividing the 
study population total 4-week costs by the total number of 
events in this period.
results Mean 4-week total costs of hypoglycaemia 
amounted to €163 (SD, €870) in T1DM and €134 (SD, 
€364) in T2DM. While productivity costs were the most 
important cost driver of hypoglycaemia in patients with 
T1DM (accounting for 72% of the total costs), costs of 
hypoglycaemia in patients with T2DM were almost entirely 
driven by costs within the healthcare sector (accounting 
for 98% of the total costs). Mean costs of a severe 
hypoglycaemic event were €828 and €508 in T1DM and 
T2DM, respectively, whereas mean costs of a non-severe 
event were almost zero.
Conclusions This study showed that the economic 
burden of severe hypoglycaemia is substantial. The 
prevention of hypoglycaemia could therefore not only 
reduce the burden for patients, but also the economic 
burden to society.
IntrOduCtIOn 
Worldwide 382 million individuals suffer 
from diabetes mellitus.1 The estimated prev-
alence of diabetes in the Netherlands was 
1.1 million in 2015.2 Between 1991 and 2014, 
the prevalence of diabetes in men has more 
than doubled, and the prevalence in women 
has increased by 50%.2 The prevalence is 
expected to increase further because of the 
ageing population and due to an increase in 
the number of people being overweight or 
having other risk factors for diabetes.3 
Patients with diabetes mellitus are at risk for 
hypoglycaemia, which is caused by medications 
used to treat diabetes mellitus, such as insulin 
or oral hypoglycaemic medications, combined 
with reduced carbohydrate intake or increased 
activity. Khunti et al have shown that the rate of 
any hypoglycaemic event was 73.3 events per 
patient-year for type 1 diabetes (T1DM) and 
19.3 events per patient-year for type 2 diabetes 
(T2DM) treated with insulin.4 Hypoglycaemia 
is mostly associated with mild symptoms, such 
as sweating, dizziness or headache, but hypo-
glycaemia can also lead to unconsciousness or 
coma. Moreover, hypoglycaemia is associated 
with more future events.5
Besides the burden for patients, hypogly-
caemia poses an economic burden to society. 
Hypoglycaemic events can lead to healthcare 
use, such as ambulance transport, hospital 
admissions and clinical appointments. 
Healthcare costs of hypoglycaemia have been 
estimated in different countries,6–10 but the 
costs of hypoglycaemia in the Netherlands are 
unknown. In addition to the healthcare costs, 
strengths and limitations of this study
 ► In the Netherlands, 150 general practitioners and 18 
hospitals (including 2 academic hospitals) partici-
pated in the study.
 ► Patient-level data were collected using a Self-
Assessment Questionnaire (SAQ) on the impact of 
hypoglycaemia on healthcare and informal care util-
isation and productivity.
 ► For some questions from the SAQ, it was unclear 
if the resources were used as a consequence of 
a severe or non-severe event; assumptions were 
made to calculate the costs of patients with se-
vere hypoglycaemia and patients with non-severe 
hypoglycaemia.
 ► Results from the SAQ (including the results regard-
ing the number of events) might suffer from recall 
bias.
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hypoglycaemia is expected to lead to societal costs due to 
lost productivity and time costs for informal caregivers, 
but these estimates are also lacking. The aim of this study 
was therefore to calculate the per patient societal costs 
of hypoglycaemia among insulin-treated patients with 
T1DM and T2DM in the Netherlands.
MethOds
To calculate the costs of hypoglycaemia, data from the 
Global Hypoglycaemia Assessment Tool (HAT) study 
were used.4 The primary objective of the HAT study was 
to determine the percentage of patients experiencing 
at least one hypoglycaemic event during the 4-week 
follow-up period among insulin-treated patients with 
T1DM and T2DM. The HAT study was a non-interven-
tional, multicentre, 6-month retrospective and 4-week 
prospective study. Patients were invited to participate by 
their healthcare provider during routine scheduled clin-
ical appointments if they fulfilled the following inclusion 
criteria: (1) having T1DM or T2DM and treated with 
insulin for >12 months; (2) being ≥18 years at the time of 
the survey and (3) giving informed consent to participate 
in the study. Non-ambulatory patients were excluded. 
The HAT study was conducted in 24 countries. To calcu-
late the costs of hypoglycaemia in the Netherlands, Dutch 
patients were selected from the HAT study database. In 
the Netherlands, 150 general practitioners and 18 hospi-
tals (including 2 academic hospitals) participated in the 
study. Patients originated from urban and rural areas 
from all over the Netherlands. Patients were invited to 
participate during routine clinical visits and were not 
actively approached to participate otherwise.
In the HAT study, a Self-Assessment Questionnaire (SAQ) 
was used, consisting of two parts. In the first part, data 
about baseline demographics and treatment were collected. 
Additionally, questions regarding knowledge, awareness 
and perceptions of hypoglycaemia were asked. Lastly, infor-
mation about the history of severe hypoglycaemia over the 
last 6 months and non-severe hypoglycaemia over the last 
4 weeks was collected. A severe event was defined as hypo-
glycaemia which requires assistance from another person 
to administer carbohydrate and/or glucagon.11 Hypogly-
caemia resulting in hospital admission and hypoglycaemia 
requiring assistance from medical personnel but not 
requiring hospital admission were also regarded as severe in 
this study. Non-severe hypoglycaemia was defined as hypo-
glycaemia managed by the patient alone. Part 1 of the ques-
tionnaire was provided to patients during a routine clinical 
appointment with a healthcare professional, and patients 
were asked to complete and return the questionnaire 
during the visit. In the next 4 weeks, patients were asked to 
fill in a diary to capture hypoglycaemic events. After 4 weeks, 
patients were asked to complete part 2 of the questionnaire, 
which assessed the history of both severe and non-severe 
hypoglycaemia in the previous 4 weeks. Both part 1 and part 
2 of the SAQ also included questions regarding the impact 
of hypoglycaemia on healthcare and informal care utilisa-
tion and productivity. The patient questionnaire is provided 
in the online supplementary appendix 1. Figure 1 shows the 
design of the study.
Costs of hypoglycaemic events within the healthcare 
sector were calculated by combining healthcare utilisation 
as derived from the SAQ with Dutch unit costs. Unit costs 
were derived from the Dutch costing manual,12 except for 
the costs of extra blood glucose tests (these were derived 
from a report by the Dutch National Healthcare Institute 
about the reimbursement and quality of blood glucose 
test material13) and the costs of glucose administered 
by medical professionals during a hypoglycaemic event 
(these were derived from  medicijnkosten. nl14). Besides 
Figure 1 Design of the HAT study.4
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the costs within the healthcare sector, informal care costs 
were calculated by combining informal care use with time 
costs of informal caregivers which were also derived from 
the Dutch costing manual.12 In order to calculate the 
costs of hypoglycaemic events within the healthcare sector 
and the costs of informal care, the following assumptions 
were made: (1) patients admitted to a hospital as a result 
of a hypoglycaemic event arrived at the hospital with an 
ambulance; (2) 75% of patients requiring assistance from 
medical personnel but not requiring hospital admission 
was treated at home by ambulance personnel and 25% 
was treated by a general practitioner (only applicable to 
patients with severe hypoglycaemia); (3) patients requiring 
assistance from medical personnel received an intrave-
nous infusion (or injection) with glucose; (4) patients 
requiring assistance from another person (non-medical) 
to administer carbohydrate and/or glucagon were given 
assistance by an informal caregiver and this assistance 
was assumed to take 1 hour for patients with T1DM and 
3 hours for patients with T2DM; (5) patients with T1DM 
who had an additional clinical appointment with a doctor 
or nurse visited the hospital, whereas patients with T2DM 
who had an additional clinical appointment with a doctor 
or nurse visited the general practitioner.
Productivity costs were calculated by combining produc-
tivity losses as derived from the SAQ with hourly produc-
tivity costs from the Dutch costing manual.12 Hourly 
productivity costs were €32 for female patients and €38 
for male patients. To calculate the productivity costs of 
hypoglycaemic events, two additional assumptions were 
made: (6) a working day was assumed to be 8 hours (for 
patients with a full-time and part-time job); (7) patients 
arriving at work late or leaving work early were absent 
from work for half a day. Productivity costs were zero for 
students and patients who were unemployed or patients 
who were retired from work.
If a question regarding resource use remained unan-
swered, it was assumed that the patient did not use this 
specific type of resource use. Missing data regarding the 
frequency of healthcare use (if a patient indicated that he 
had used a specific type of resource use) were handled 
by imputing the mean of the available data. In this way, 
all patients were included in the calculation of total costs 
including patients with missing values on some, but not 
all variables.
Base case analyses present the per patient 4-week costs 
as derived from part 2 of the SAQ (ie, the 4 week prospec-
tive study). Results were reported separately for patients 
with T1DM and T2DM. Within these two categories, a 
further distinction was made between patients with hypo-
glycaemia including at least one severe event and for 
patients with non-severe events only. Results of part 1 of 
the SAQ (ie, 6-month retrospective study) were provided 
in the online supplementary materials.
The impact of assumptions 2, 4 and 7 on the total 
4-week costs of patients experiencing hypoglycaemia were 
tested in univariate sensitivity analyses. First, the propor-
tion of patients treated at home by a general practitioner 
or ambulance personnel was varied, that is, 50% or 0% 
treated at home by a general practitioner (instead of 
25%) and 50% or 100% treated by ambulance personnel 
(instead of 75%). Second, the duration of assistance by 
an informal caregiver was doubled, that is, 2 hours for 
T1DM (instead of 1 hour) and 6 hours for T2DM (instead 
of 3 hours). Third, the hours that patients were absent 
from work if they indicated that they arrived at work late 
or left work early were halved, that is, 2 hours instead of 
4 hours. In addition to these assumptions, the impact of 
higher unit costs (+20%) of an ambulance was studied.
Besides the per patient total 4-week costs of patients 
experiencing hypoglycaemia, costs were calculated per 
hypoglycaemic event. To calculate these costs, the study 
population total 4-week costs were divided by the total 
number of events in this period. The total number of 
events was derived from the SAQ and patient diary. Since 
number of events according to the SAQ and patient diary 
differed, two point estimates of the costs of an event were 
provided.
Additionally, the total costs of hypoglycaemia among 
insulin-treated patients with T1DM and T2DM in the 
Netherlands were estimated using information on 
the total number of insulin-users in the Netherlands. 
According to the Dutch Foundation for Pharmaceutical 
Statistics (SFK), there were 310 000 insulin-users in the 
Netherlands in 2014.15 Assuming that all patients with 
T1DM use insulin and that the estimated prevalence 
of diabetes in the Netherlands was 1.1 million in 2015, 
and 9% (ie, 99 000 patients) had T1DM,2 the estimated 
number of insulin-users is 99 000 in T1DM and 211 000 
in T2DM (ie, 310 000 minus 99 000). These numbers 
were then multiplied by the proportion of patients expe-
riencing hypoglycaemia, and the per patient 4-week costs 
(extrapolated to yearly costs) of these latter patients.
All costs were reported in Euro 2016. Wherever neces-
sary, costs were adjusted to 2016 values using the consumer 
price index derived from Statistics Netherlands.16
results
Patient and disease characteristics
Six hundred and thirty-three patients returned part 2 of 
the SAQ, that is, 142 patients with T1DM and 491 patients 
with T2DM. Table 1 shows the patient and disease char-
acteristics. The median age was 46 years for patients with 
T1DM and 68 years for patients with T2DM. The dura-
tion of diabetes was 18.6 years (SD, 12.1) and 14.2 years 
(SD, 8.0) for patients with T1DM and T2DM, respectively. 
Patients with T2DM used insulin, on average, for 7.7 years 
(SD, 6.1). Levels of glycaemic control (ie, HbA1c) were 
similar across patients with T1DM and T2DM (59.3 mmol/
mol (7.3%) vs 57.7 mmol/mol (7.6%)).
In the 4 weeks after baseline, 92% of the patients with 
T1DM and 43% of the patients with T2DM experienced 
one or more hypoglycaemic events. Of these patients, 
10% and 15% experienced at least one severe event, and 
almost all these patients (ie, 98% and 96%) experienced 
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at least one non-severe event. Fifty-one per cent and 32% 
of the patients with T1DM and T2DM who experienced 
hypoglycaemia, respectively, experienced (a) nocturnal 
hypoglycaemic event(s).
healthcare utilisation and informal care utilisation
Table 2 shows the healthcare utilisation and informal 
care utilisation of those patients who experienced hypo-
glycaemia in the 4 weeks after baseline (patients without 
hypoglycaemia were excluded from the analyses). Only 43 
patients (13%) of the population had at least one event 
requiring (1) hospital admission (T1DM, 2%; T2DM, 
10%); (2) assistance from medical personnel but not 
requiring hospital admission (T1DM, 1%; T2DM, 2%); 
and/or (3) assistance from another person to administer 
carbohydrate and/or glucagon (T1DM, 9%; T2DM, 6%). 
Most patients (T1DM, 98%; T2DM, 96%) also had one or 
more events that they could manage themselves.
Actions undertaken by patients as a result of hypo-
glycaemic events are also presented in table 2. Fifteen 
per cent (T1DM, 21%; T2DM 11%) of the population 
addressed a hypoglycaemic event at the next scheduled 
clinic visit, 2% (T1DM, 2%; T2DM 1%) attended an 
additional clinical appointment with a doctor or nurse, 
8% (T1DM, 7%; T2DM 8%) made additional telephone 
contacts with a doctor or nurse, 1% (T1DM, 1%; T2DM 
1%) consulted another healthcare professional and 68% 
(T1DM, 70%; T2DM 67%) did not consult a doctor, nurse 
or healthcare professional if they experienced a hypogly-
caemic event (note that this is the average of patients 
with hypoglycaemia including at least one severe event or 
non-severe events only).
Also, 26% (T1DM, 27%; T2DM 25%) of the population 
increased the quantity of carbohydrates or number of 
snacks in diet, 7% (T1DM, 8%; T2DM 6%) reduced the 
amount of sport or physical exercise, 29% (T1DM, 39%; 
T2DM 22%) decreased the insulin dose, 15% (T1DM, 
16%; T2DM 14%) skipped the insulin dose, 53% (T1DM, 
58%; T2DM 50%) increased the number of blood glucose 
checks per day and 11% (T1DM, 16%; T2DM 8%) made 
any other change to diabetes treatment.
Per patient 4-week healthcare utilisation and informal care 
costs
Table 3 presents the 4-week healthcare utilisation costs 
and informal care costs of patients who experienced 
Table 1 Patient and disease characteristics
All patients (n=633) T1DM (n=142) T2DM (n=491)
Age, median (range) 65 (18–92) 46 (18–82) 68 (30–92)
Sex, n (%)
  Female 319 (50) 79 (56) 240 (49)
  Male 314 (50) 63 (44) 251 (51)
Years with diabetes, mean (SD) 15.2 (9.3) 18.6 (12.1) 14.2 (8.0)
Years on insulin, mean (SD) 10.0 (9.0) 17.9 (12.2) 7.7 (6.1)
HbA1c, mmol/mol, mean (SD) 58.0 (11.8) 59.3 (12.6) 57.7 (11.5)
HbA1c, %, mean (SD) 7.5 (1.3) 7.3 (1.2) 7.6 (1.4)
Checks blood glucose levels, n (%)
  Yes 618 (98) 141 (99) 477 (97)
  No 12 (2) 1 (1) 11 (2)
  Missing 3 (0) 0 (0) 3 (1)
Method of diabetes treatment, n (%)
  Insulin – short-acting 323 (51) 103 (73) 220 (45)
  Insulin – long-acting 444 (70) 79 (56) 365 (74)
  Insulin – mixed 114 (18) 6 (4) 108 (22)
  Insulin pump 60 (9) 52 (37) 8 (2)
  Oral glucose lowering drugs 152 (24) 6 (4) 146 (30)
  Injectable glucose-lowering treatments excluding insulin 8 (1) 0 (0) 8 (2)
All patients (n=612)* T1DM (n=141) T2DM (n=471)
Number of patients with one or more hypoglycaemic events, n (%) 332 (54) 130 (92) 202 (43)
  Severe hypoglycaemia 43 (13) 13 (10) 30 (15)
  Non-severe hypoglycaemia 322 (97) 128 (98) 194 (96)
  Nocturnal hypoglycaemia 130 (39) 66 (51) 64 (32)
*Data from 21 patients were missing.
T1DM, type 1 diabetes; T2DM, type 2 diabetes.
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Table 2 Healthcare utilisation, informal care utilisation and additional actions of patients experiencing hypoglycaemia in 4 
weeks after baseline
All 
(n=332) T1DM (n=130) T2DM (n=202)
All
(n=332)
All 
(n=130)
Patients 
with SH 
(n=13)
Patients 
with NSH 
(n=117)*
All 
(n=202)
Patients 
with SH 
(n=30)
Patients 
with NSH 
(n=172)*
Patients indicated the following hypoglycaemic events (in the last 4 weeks)†
  Event resulting in hospital admission, n (%) 23 (7) 3 (2) 3 (23) 0 (0) 20 (10) 20 (67) 0 (0)
  Times admitted, mean (SD) 1.0 (0.0) 1.0 (0.0) 1.0 (0.0) – 1.0 (0.0) 1.0 (0.0) – 
  Admission length (days), mean (SD) 1.1 (0.4) 1.7 (1.2) 1.7 (1.2) – 1.0 (0.0) 1 (0.0) – 
  Event requiring assistance from medical 
personnel but not requiring hospital admission, 
n (%)
6 (2) 1 (1) 1 (8) 0 (0) 5 (2) 5 (17) 0 (0)
  Number of episodes, mean (SD) 1.0 (0.0) 1.0 (0.0) 1.0 (0.0) – 1.0 (0.0) 1.0 (0.0) – 
  Event requiring assistance from another person 
to administer carbohydrate and/or glucagon 
(informal care), n (%)
24 (7) 12 (9) 12 (92) 0 (0) 12 (6) 12 (40) 0 (0)
  Number of episodes, mean (SD) 1.8 (1.3) 1.5 (0.8) 1.5 (0.8) – 2.2 (1.6) 2.2 (1.6) – 
  Event managed by the patient, n (%) 322 (97) 128 (98) 12 (92) 116 (99) 194 (96) 23 (77) 171 (99)
  Number of episodes, mean (SD) 5.1 (5.2) 8.6 (6.3) 10.5 (8.1) 8.5 (6.0) 2.7 (2.4) 2.0 (1.6) 2.8 (2.5)
  Event occurred at night, n (%) 130 (39) 66 (51) 9 (69) 57 (49) 64 (32) 12 (40) 52 (30)
  Number of episodes, mean (SD) 2.1 (1.8) 2.5 (2.2) 3.3 (3.1) 2.4 (2.1) 1.6 (1.0) 1.7 (1.2) 1.6 (0.9)
Patients indicated the following actions (if they experienced a hypoglycaemic event in the last 4 weeks)
  Addressed the hypoglycaemic event at next 
scheduled clinic visit, n (%)
50 (15) 27 (21) 6 (46) 21 (18) 23 (11) 6 (20) 17 (10)
  Attended additional clinical appointments with 
doctor/nurse, n (%)
5 (2) 2 (2) 1 (8) 1 (1) 3 (1) 1 (3) 2 (1)
  Number of extra appointments, mean (SD) 1.7 (0.8) 2.3 (0.9) 3.0 (0.0) 1.7 (0.0) 1.2 (0.4) 1.7 (0.0) 1.0 (0.0)
  Rescheduled clinic appointment for an earlier 
time, n (%)
1 (0) 1 (1) 1 (8) 0 (0) 0 (0) 0 (0) 0 (0)
  Made additional telephone contacts with 
doctor/nurse, n (%)
26 (8) 9 (7) 5 (38) 4 (3) 17 (8) 5 (17) 12 (7)
  Number of telephone contacts, mean (SD) 2.0 (1.2) 2.2 (1.3) 2.6 (1.5) 1.8 (1.0) 1.9 (1.1) 1.6 (0.5) 2.0 (1.3)
  Consulted another healthcare professional, n 
(%)
2 (1) 1 (1) 0 (0) 1 (1) 1 (1) 0 (0) 1 (1)
  Did not consult a doctor/nurse/healthcare 
professional, n (%)
227 (68) 91 (70) 5 (38) 86 (74) 136 (67) 11 (37) 125 (73)
  Increased the quantity of carbohydrates or 
number of snacks in diet, n (%)
86 (26) 35 (27) 3 (23) 32 (27) 51 (25) 6 (20) 45 (26)
  Reduced the amount of sport or physical 
exercise, n (%)
24 (7) 11 (8) 3 (23) 8 (7) 13 (6) 1 (3) 12 (7)
  Decreased insulin dose, n (%) 96 (29) 51 (39) 7 (54) 44 (38) 45 (22) 7 (23) 38 (22)
  Skipped insulin dose, n (%) 49 (15) 21 (16) 2 (15) 19 (16) 28 (14) 7 (23) 21 (12)
  Increased the number of blood glucose checks 
per day, n (%)
176 (53) 76 (58) 8 (62) 68 (58) 100 (50) 17 (57) 83 (48)
  Number of extra checks, mean (SD) 2.0 (0.7) 1.9 (0.8) 2.1 (0.8) 1.9 (0.8) 2.0 (0.7) 2.2 (0.8) 2.0 (0.7)
  Number of days, mean (SD) 4.3 (5.1) 5.5 (4.1) 5.5 (3.9) 5.5 (4.2) 3.4 (5.5) 5.9 (8.9) 2.9 (4.5)
  Made any other changes to diabetes treatment, 
n (%)
38 (11) 21 (16) 3 (23) 18 (15) 17 (8) 3 (10) 14 (8)
*Note that these categories include patients with (a) non-severe event(s) only (and two patients (1 T1DM patient and 1 T2DM patient) with a 
nocturnal event only).
†Note that the percentages do not count to 100%, because patients can have multiple hypoglycaemic events.
NSH, non-severe hypoglycaemia; SH, severe hypoglycaemia; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
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hypoglycaemia in the 4 weeks after baseline. Mean total 
4-week healthcare and informal care costs were €98 (SD, 
€325). Mean costs were higher for patients with T2DM than 
for patients with T1DM; €131 (SD, €363) compared with 
€46 (SD, €248). Mean costs of patients with hypoglycaemia 
including at least one severe event were €426 (SD, €696) 
and €863 (SD, €512) in T1DM and T2DM, respectively, 
compared with €4 (SD, €16) and €4 (SD, €12) in T1DM 
and T2DM, for patients with non-severe events only.
Productivity losses
Productivity losses are presented in table 4. Of the 
patients with a full-time or part-time job, 4% reported sick 
leave (T1DM, 5%; T2DM, 2%) with a mean of 6 days (SD, 
8). Additionally, 8% (T1DM, 12%; T2DM, 2%) and 6% 
(T1DM, 9%; T2DM, 0%) of the patients with a full-time 
or part-time job arrived at work late or left work early for 
≥1 days, respectively.
Per patient total 4-week costs
Table 5 shows the per patient total 4-week costs of patients 
who experienced hypoglycaemia. Mean total 4-week 
costs were €145 (SD, €613). Mean costs were €163 (SD, 
€870) for patients with T1DM and €134 (SD, €364) for 
patients with T2DM. While productivity costs were the 
most important cost driver of hypoglycaemia in patients 
with T1DM (accounting for 72% of the total costs), costs 
of hypoglycaemia in patients with T2DM were almost 
entirely driven by costs within the healthcare sector 
(accounting for 98% of the total costs).
Mean costs of patients with hypoglycaemia including at 
least one severe event were €1401 (SD, €2,497) and €863 
(SD, €512) in T1DM and T2DM, respectively, compared 
with €26 (SD, €81) and €7 (SD, €41) in T1DM and 
T2DM for patients with non-severe events only. The mean 
total costs of patients with T1DM experiencing at least 
one severe event were largely driven by two patients, one 
with sick leave from work for 21 days and one with sick 
leave from work for 10 days.
sensitivity analyses
Results of the sensitivity analyses suggest that the impact 
of the assumptions on the mean total 4-week costs of 
patients experiencing hypoglycaemia was limited. If the 
proportion of patients treated at home by ambulance 
personnel was decreased to 50%, total 4-week costs 
would decrease from €145 (SD, €613) to €143 (SD, 
€609). If the proportion of patients treated at home 
by ambulance personnel was increased to 100%, total 
4-week costs would increase to €148 (SD, €617). If 
the duration of assistance by an informal caregiver was 
doubled to 2 hours for T1DM and to 6 hours for T2DM, 
total 4-week costs would increase to €149 (SD, €616). 
If the hours that patients were absent from work were 
halved to 2 hours, total 4-week costs would decrease 
to €137 (SD, €600). Lastly, if ambulance costs were 
Table 3 Per patient healthcare utilisation costs and informal care costs of patients experiencing hypoglycaemia in 4 weeks 
after baseline
Unit costs
(€) 2016
All (n=332) T1DM (n=130) T2DM (n=202)
All (n=332) All (n=130)
Patients 
with SH 
(n=13)
Patients 
with NSH 
(n=117) All (n=202)
Patients 
with SH 
(n=30)
Patients with 
NSH (n=172)
Patients indicated the following hypoglycaemia events (in the last 4 weeks)
  Event resulting in hospital admission, 
mean costs (SD)
€480.29* €79 (€296) €33 (€226) €329 (€665) €0 (€0) €109 (€331) €737 (€530) €0 (€0)
  Event requiring assistance from medical 
personnel but not requiring hospital 
admission, mean costs (SD)
476.51† €9 (€64) €4 (€42) €37 (€134) €0 (€0) €12 (€75) €81 (€183) €0 (€0)
  Event requiring assistance from another 
person to administer carbohydrate and/or 
glucagon (informal care), mean costs (SD)
€14.13 €4 (€21) €2 (€7) €20 (€12) €0 (€0) €5 (€27) €37 (€62) €0 (€0)
Patients indicated the following actions (if they experienced a hypoglycaemic event in the last 4 weeks)
  Attended additional clinical appointments 
with doctor/nurse, mean costs (SD)
€91.82/€33.30 €2 (€18) €3 (€28) €21 (€76) €1 (€14) €1 (€5) €2 (€10) €0 (€4)
  Made additional telephone contacts with 
doctor/nurse, mean costs (SD)
€17.15 €3 (€11) €3 (€11) €17 (€27) €1 (€6) €3 (€10) €5 (€11) €2 (€10)
  Consulted another healthcare professional, 
mean costs (SD)
€14.13–€17.15 €0 (€1) €0 (€2) €0 (€0) €0 (€2) €0 (€1) €0 (€0) €0 (€1)
  Increased the number of blood glucose 
checks per day, mean costs (SD)‡
€0.27 €1 (€2) €2 (€2) €2 (€2) €2 (€2) €1 (€3) €2 (€5) €1 (€2)
Total healthcare utilisation and informal care 
costs, mean costs (SD)
€98 (€325) €46 (€248) €426 (€696) €4 (€16) €131 (€363) €863 (€512) €4 (€12)
*Besides inpatient day(s) (€480.29) it is assumed this event required an ambulance (€618.53) and an intravenous infusion (or injection) with glucose (€6.63).
†Besides an ambulance (€618.53; 75%) or visit by a general practitioner (€50.45; 25%), it is assumed that this event required an intravenous infusion (or injection) 
with glucose (€6.63; 75% and €6.12; 25%).
‡Patients could choose between 1, 2 or 3+ extra tests. If they reported 3+ tests, costs of blood glucose checks were based on the costs of three tests.
NSH, non-severe hypoglycaemia; SH, severe hypoglycaemia; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
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increased with 20%, total 4-week costs would increase to 
€156 (SD, €637).
The impact of the assumptions on the mean total 
4-week costs of patients with hypoglycaemia including at 
least one severe event and on the costs of patients with 
non-severe events only was also limited.
Cost per hypoglycaemic event
Mean costs per hypoglycaemic event are presented in 
table 5 and amounted to €19 for patients with T1DM and 
€47 for patients with T2DM (€16 and €46 if the number 
of events as registered in the patient diary was used (note 
that the number of events according to the patient diary 
were consistently higher than in the SAQ)). Mean costs of 
a severe event were €828 and €508 in T1DM and T2DM, 
respectively (€552 and €1036 if the number of events 
as registered in the patient diary was used), whereas the 
costs of a non-severe event were almost zero.
total cost of hypoglycaemia in the netherlands
Given that 92% of the T1DM population experience at 
least one hypoglycaemic event in a 4-week period, and 
that the mean total 4-week costs are €163 (95% CI €12 to 
€314), total 4-week costs in the entire Dutch T1DM popu-
lation were estimated to amount to €14.8 million. Total 
4-week costs in the entire Dutch T2DM population were 
estimated to amount to €12.2 million given that 43% of 
the insulin-treated T2DM population experience at least 
one hypoglycaemic event and that the mean total 4-week 
costs are €134 (95% CI €83 to €184). Total yearly costs of 
hypoglycaemia were estimated to be €352.3 million for the 
entire patient T1DM and T2DM population in the Neth-
erlands (healthcare costs, €201.4 million; informal care 
costs, €8.3 million; productivity costs, €142.6 million). 
Using the boundaries of the 95% CI of the per patient 
total 4-week costs, total yearly costs of hypoglycaemia in 
the Netherlands were estimated to range from €112.5 to 
€590.8 million.
Per patient total costs based on part 1 of the sAQ
Mean total 6-month costs of patients experiencing hypo-
glycaemia including at least one severe event were €1132 
(SD, 2933) for patients with T1DM and €586 (SD, 1439) 
for patients with T2DM using part 1 of the questionnaire, 
corresponding to €189 and €98 per month. The costs 
within the healthcare sector are the most important cost 
driver of hypoglycaemia in both patients with T1DM and 
T2DM (see the online supplementary tables 1–4).
dIsCussIOn
This is the first study providing information on the costs 
of hypoglycaemia among insulin-treated patients with 
T1DM and T2DM in the Netherlands. The study shows 
that the economic burden is substantial. Mean 4-week 
costs of patients who experienced hypoglycaemia were 
€145 (SD, €613). In the Netherlands in 2011, the costs of 
diabetes care amounted to 1.7 billion Euros.17 Healthcare 
costs of hypoglycaemia in the Netherlands were estimated 
Table 4 Productivity losses of patients experiencing hypoglycaemia in 4 weeks after baseline
All 
(n=332) T1DM (n=130) T2DM (n=202)
All
(n=332)
All 
(n=130)
Patients 
with 
SH (n=13)
Patients with 
NSH (n=117)
All 
(n=202)
Patients 
with 
SH (n=30)
Patients with 
NSH (n=172)
Employment status - n (%) 
  Full-time employment 80 (24) 48 (37) 5 (38) 43 (37) 32 (16) 3 (10) 29 (17)
  Part-time employment 65 (20) 46 (35) 6 (46) 40 (34) 19 (9) 2 (7) 17 (10)
  Student 7 (2) 7 (5) 0 (0) 7 (6) 0 (0) 0 (0) 0 (0)
  Pensioned 142 (43) 14 (11) 0 (0) 14 (12) 128 (63) 19 (63) 109 (63)
  Unemployed 11 (3) 7 (5) 2 (15) 5 (4) 4 (2) 1 (3) 3 (2)
  Other 23 (7) 6 (5) 0 (0) 6 (5) 17 (8) 5 (17) 12 (7)
  Missing 4 (1) 2 (2) 0 (0) 2 (2) 2 (1%) 0 (0) 2 (1)
Within patients being full-time or part-time employed
n=145 n=94 n=11 n=83 n=51 n=5 n=46
  Sick leave from work, n (%) 6 (4) 5 (5) 5 (45) 0 (0) 1 (2) 0 (0) 1 (2)
   Number of days, mean (SD) 6.0 (8.1) 7.0 (8.7) 7.0 (8.7) – 1.0 (0.0) – 1.0 (0.0)
  Arrived at work late, n (%) 12 (8) 11 (12) 3 (27) 8 (10) 1 (2) 0 (0) 1 (2)
   Number of days, mean (SD) 2.0 (1.5) 2.0 (1.5) 4.0 (1.7) 1.3 (0.5) 2.0 (0.0) – 2.0 (0.0)
  Left work early, n (%) 8 (6) 8 (9) 3 (27) 5 (6) 0 (0) 0 (0) 0 (0)
   Number of days, mean (SD) 1.9 (1.5) 1.9 (1.5) 2.0 (1.0) 1.8 (1.8) – – – 
NSH, non-severe hypoglycaemia; SH, severe hypoglycaemia; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
 o
n
 3 D
ecem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019864 on 25 March 2018. Downloaded from 
8 de Groot S, et al. BMJ Open 2018;8:e019864. doi:10.1136/bmjopen-2017-019864
Open Access 
to be €201.4 million per year, corresponding to 12% of 
the total healthcare costs of diabetes in the Netherlands. 
The total yearly costs of hypoglycaemia in the Nether-
lands, including informal care costs and productivity 
costs, were estimated to be €352.3 million.
The healthcare costs of hypoglycaemia in the Nether-
lands might seem relatively high with respect to the total 
costs of diabetes, but the total costs of diabetes might 
miss important diabetes-related costs, such as the costs 
of complications (eg, heart attack, stroke, eye problems 
and kidney disease). Total yearly costs of hypoglycaemia 
have been estimated in different countries,6–10 and all 
of these estimates are considerably lower than the costs 
we estimated. A comparison of healthcare costs between 
countries is complicated by practice variation, differ-
ences in the incentives to physicians and institutions and 
differences in relative and absolute prices.18 These differ-
ences should be taking into account when making inter-
national comparisons of healthcare costs. Nevertheless, 
possible explanations for the observed differences might 
be: first, one Swedish study was limited to the total yearly 
costs of T2DM,6 whereas we estimated total yearly costs 
of both T1DM and T2DM. Furthermore, this study only 
assessed costs of hypoglycaemic events that were classi-
fied as severe events in our study. Second, some studies 
were limited to healthcare costs,8 9 while we also took into 
account informal care costs and productivity costs. Third, 
different assumptions were made regarding the incidence 
of hypoglycaemia: while one study assumed an event rate 
of 0.09 per patient with T2DM per year (ie, 0.24 in insulin 
users and 0.04 in patients using oral antidiabetic agents),6 
the incidence among insulin-treated patients with T2DM 
in our study varied from 571 to 584 events in the 4-week 
follow-up period (ie, 15.8–16.2 per patient per year). 
Fourth, the number of patients in other countries was 
considerably lower than in the Netherlands.
Interestingly, the costs per hypoglycaemic event as 
calculated in our study were considerably lower than the 
costs as estimated in other studies.6 7 Again it should be 
noted that comparing healthcare costs between countries 
is complicated. Nevertheless, one of the explanations for 
the difference is the definition of a severe event which 
was limited to events resulting in hospitalisation in one 
study.6 An Italian study presented resource utilisation 
and productivity losses per person-years, which compli-
cates comparisons of their estimates of cost per episode 
Table 5 Per patient total 4-week costs of patients experiencing hypoglycaemia and costs per event
All (n=332) T1DM (n=130) T2DM (n=202)
All
(n=332) All (n=130)
Patients with 
SH (n=13)
Patients 
with NSH 
(n=117) All (n=202)
Patients with 
SH (n=30)
Patients 
with NSH 
(n=172)
Per patient total 4-week costs
  Costs within the healthcare sector 
(including informal care), mean costs 
(SD) (min–max)
€98 (€325)
(€0–€2101)
€46 (€248)
(€0–€2101)
€426 (€696)
(€14–€2101)
€4 (€16)
(€0–€153)
€131 (€363)
(€0–€1654)
€863 (€512)
(€42–€1654)
€4 (€12)
(€0–€78)
  Productivity costs, mean costs (SD) 
(min–max)
€47 (€412)
(€0–€6577)
€117 (€652)
(€0–€6577)
€975 (€1905)
(€0–€6577)
€22 (€77)
(€0–€638)
€3 (€36)
(€0–€510)
€0 (€0)
(€0–€0)
€3 (€39)
(€0–€510)
  Per patient total 4-week costs of 
patients experiencing hypoglycaemia, 
mean costs (SD) (min–max)
€145 (€613)
(€0–€8678)
€163 (€870)
(€0–€8678)
€1401 (€2497)
(€14–€8678)
€26 (€81)
(€0–€638)
€134 (€364)
(€0–€1654)
€863 (€512)
(€42–€1654)
€7 (€41)
(€0–€525)
Costs per event
  Study population total 4-week 
costs of patients experiencing 
hypoglycaemia
€48 140 €21 190 €18 213 €3042 €27 068 €25 890 €1204
  Number of events based on SAQ* 1700 1129 22† 981 571 51‡ 473
  Total costs per event (based on SAQ) €28 €19 €828 €3 €47 €508 €3
  Number of events based on patient 
diary§
1923 1339 33 1139 584 25 483
  Total costs per event (based on 
patient diary)¶
€25 €16 €552 €3 €46 €1036 €2
*The number of events excludes nocturnal events in order to prevent double counting. The number of events in patients with at least one 
severe event excludes non-severe events.
†Two patients experienced three events requiring assistance from another person to administer carbohydrate and/or glucagon, and two 
patients had two of these events, which increases the total number of events in the population.
‡Six patients experienced more than one event requiring assistance from another person to administer carbohydrate and/or glucagon, with 
one patients having six of these events.
§Number of events in patients with SH and NSH are limited to the number of severe and non-severe events, respectively, as reported within 
these groups.
¶Please note that the SD could not be calculated because costs per event were calculated by dividing total population costs by the total 
number of events in the population, but is expected to be substantial.
NSH, non-severe hypoglycaemia; SH, severe hypoglycaemia; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
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to the estimates in the current study.10 The cost estimates 
in that study seem to be higher because of a longer stay 
in hospital and larger productivity losses for patients and 
caregivers. In contrast to the Italian study, work days lost 
by family members are not taken into account in our 
study, to avoid possible double counting with informal 
care time. A Danish study found lower costs per hypo-
glycaemic event than the costs we calculated, but in this 
study, costs were limited to healthcare costs.9
Some limitations to the data and methods deserve 
mentioning. First, there is large variation in the per 
patient costs. This can be explained by the skewed distri-
bution of the data, that is, a small number of patients has 
very high costs (eg, while the mean total 4-week costs are 
€145 (SD, 613), 25 out of 332 patients (8%) have costs 
>€1000). This is frequently observed in costing studies. 
Further research, preferably with larger sample sizes, 
should confirm the results of our study.
Second, there is a large discrepancy between the per 
patient costs of patients experiencing hypoglycaemia 
including at least one severe event between part 1 and 
part 2 of the SAQ. The monthly costs based on part 1 of 
the questionnaire are much lower than the costs based on 
part 2 (ie, €188 and €100 vs €1401 and €863 in T1DM 
and T2DM, respectively). There might be several expla-
nations: first, the results from part 1 might suffer from 
recall bias, since patients were asked about healthcare 
use in the previous 6 months and productivity losses in 
the previous year and as a consequence they might not 
remember using healthcare or being absent from work. 
As a result, the costs based on part 1 of the SAQ might 
be underestimated. Second, the results from part 2, espe-
cially those related to T1DM, are largely driven by two 
patients (ie, one with sick leave from work for 21 days and 
one with sick leave from work for 10 days).
Third, not all patients (88%) who participated in the 
study and completed part 1 of the SAQ filled in part 2 of 
the SAQ and the diary. A comparison of the baseline char-
acteristics (ie, age, gender, years with diabetes and years 
on insulin) of the patients who did and did not complete 
part 2 did not show significant differences, suggesting that 
the patients completing part 2 are representative of all 
patients participating in the HAT study (although non-sig-
nificant findings might be related to small sample size). 
The only significant difference we found was a difference 
in age, that is, the patients who did not complete part 2 
were younger than the patients who did complete part 2. 
This is explained partly by the type of diabetes among the 
two groups, that is, 15% of the patients with T1DM did 
not complete part 2 compared with 8% of the patients 
with T2DM. However, since all results are reported sepa-
rately for patients with T1DM and T2DM, the impact 
of the potential under-representation of patients with 
T1DM is limited. It is further assumed that the samples 
(T1DM and T2DM) reflect the total insulin-treated 
T1DM and T2DM population (treated with insulin for at 
least 12 months) in the Netherlands, because all consecu-
tive patients fulfilling the inclusion criteria were enrolled 
during routine scheduled clinical appointments with 
their healthcare provider. Demographic properties (age 
and gender) were similar in our study compared with the 
overall diabetes population in the Netherlands.19 Studies 
in other Western European countries show similar results 
with respect to the incidence and prevalence of hypogly-
caemic events.4 20 The HAT study only included patients 
using insulin for at least 12 months. As patients who started 
using insulin more recently receive extra training about 
the risks of hypoglycaemia, they might be more focused 
on hypoglycaemic events and might be more in control 
when these occur. Consequently, the number of hypo-
glycaemic events might be lower compared with patients 
who are treated with insulin for >12 months. Since the 
number of newly treated patients (<12 months insulin 
use) is likely to be low, the impact on the results would be 
limited.4 Nonetheless, these patients were excluded from 
the analyses, so that the sample consisted of patients in 
which changes in insulin treatment were not expected.
Fourth, the incidence of hypoglycaemic events 
according to the patient diary was higher than reported 
in the SAQ. As mentioned by Khunti et al4, results from 
the SAQ might suffer from recall bias and the number 
of events might therefore be underestimated.4 On the 
contrary, double counting might occur in the SAQ in case 
a patient had an event resulting in hospital admission or 
an event requiring assistance from medical personnel but 
not requiring hospital admission and required assistance 
from another person for the same event. As a conse-
quence, results from the SAQ might be overestimated. 
Although we present the costs per event based on both 
incidences, we believe that the cost per event based on the 
incidence as estimated from the SAQ is more reliable, as 
data on healthcare utilisation and frequency of hypogly-
caemic events were derived from the same source. Never-
theless, the number of severe events seems relatively high, 
that is, 22 events in 13 patients with T1DM and 51 events 
in 30 patients with T2DM in a 4-week period. Two patients 
with T1DM experienced three events requiring assistance 
from another person to administer carbohydrate and/or 
glucagon and two patients had two of these events, which 
increases the total number of events in the population. 
Similarly, there were six patients with T2DM with more 
than one event requiring assistance from another person 
to administer carbohydrate and/or glucagon with one 
patients having six of these events.
Fifth, productivity losses due to a reduced ability to 
work efficiently (ie, presenteeism) were not taken into 
account, because no data about presenteeism were avail-
able. Since it seems plausible that patients who experi-
enced a hypoglycaemic event but are not absent from 
work will work less efficiently, total productivity costs 
may be underestimated. Additionally productivity costs 
may be underestimated, because productivity losses of 
unpaid work were neglected (eg, household activities). 
In contrast, productivity losses could be overestimated 
because patients might have attributed productivity losses 
to hypoglycaemia that were actually related to other 
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causes (eg, comorbidities). However, as the questionnaire 
specifically asks for productivity losses that were related to 
hypoglycaemia, such a potential overestimation is likely 
to be limited. Future studies could use a control group 
consisting of patients with diabetes but without hypogly-
caemia to address this issue.
In conclusion, this study showed that the economic 
burden of hypoglycaemia is substantial, especially the 
burden of severe events. Important differences between 
the costs of hypoglycaemia in T1DM and T2DM were 
found. While productivity costs are the most important 
cost driver of hypoglycaemia in patients with T1DM, costs 
within the healthcare sector are the most important cost 
driver of hypoglycaemia in patients with T2DM. As the 
costs of hypoglycaemia are substantial, the prevention 
of hypoglycaemia could not only reduce the burden for 
patients, but also the economic burden to society, if the 
costs of prevention are smaller than the costs of hypogly-
caemia. Increasing awareness among physicians about 
the frequent occurrence of hypoglycaemia is essential 
to prevent hypoglycaemia; as patients might not always 
report these for various reasons, including fear or shame, 
or because they do not see the relevance, physicians might 
be unaware of (the frequency of) hypoglycaemic events. 
Furthermore, it is important to incorporate the costs of 
hypoglycaemia in cost-effectiveness analysis of treatments 
for diabetes, for example, to study potential cost-savings if 
treatment reduces the number of (severe) hypoglycaemic 
events. However, given the large variation in costs per 
event, the results from this study should be used carefully 
and tested using sensitivity analyses to acknowledge the 
uncertainty around our estimates.
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